Lipid 8
Version 1.5c84877e · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Lipid 8 |
| Synonyms | 2-[Di-(9Z,12Z)-9,12-octadecadien-1-ylamino]ethyl 4-(dimethylamino)butanoate;Lipid-8，Lipid8 |
| SMILES | CCCCC/C=C\C/C=C\CCCCCCCCN(CCOC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC |
| Formula | C44H82N2O2 |
| M.Wt | 671.13 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer-Adv. Mater. 2022, 34, 2106350 |
Lipid 8 iLNPs were used to deliver CRISPR-Cas9 mRNA and sgRNA which targeted to the PLK1 gene. The safety and excellent intracerebral diffusion performance of lipid 8 iLNPs ensured that the survival of murine glioblastoma multiforme (GBM) mice was extended. The median survival was extended by approximately 50% and the overall survival was increased by 30%. The treatment of metastatic adenocarcinoma was executed by the EGFRtargeted lipid 8 iLNPs. These iLNPs possessed the ability of tumor targeting, which could increase the accumulation of CRISPR-Cas9 mRNA and sgRNA within the tumor cells. After a single intraperitoneal administration, 80% PLK1 gene was edited and the overall survival of mice with high-grade ovarian cancer malignant ascites was enhanced by 80% . These results demonstrate the clinical potential of CRISPR-Cas9 gene editing system can be delivered by iLNPs for treating tumors, and provide new ideas for tumor gene therapy.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →